NCT05630612View on ClinicalTrials.gov

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

July 18, 2024

Study Completion Date

September 1, 2027

Conditions
ANCA Associated VasculitisCardiovascular DiseasesKidney Diseases
Interventions
DRUG

Sparsentan

6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.

Trial Locations (1)

EH16 4TJ

Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh

All Listed Sponsors
collaborator

Travere Therapeutics, Inc.

INDUSTRY

lead

University of Edinburgh

OTHER